pomalidomide has been researched along with rrx-001 in 2 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (rrx-001) | Trials (rrx-001) | Recent Studies (post-2010) (rrx-001) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 45 | 5 | 45 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Anderson, KC; Chauhan, D; Das, A; Das, DS; Oronsky, B; Ray, A; Richardson, P; Scicinski, J; Song, Y; Tian, Z | 1 |
1 review(s) available for pomalidomide and rrx-001
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
1 other study(ies) available for pomalidomide and rrx-001
| Article | Year |
|---|---|
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azetidines; Bortezomib; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Epigenomics; Heterografts; Humans; Hypoxia; Mice; Multiple Myeloma; Nitro Compounds; Thalidomide; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7 | 2016 |